Europe Bispecific Antibodies Market Size, Share & Industry Trends Analysis Report

Europe Bispecific Antibodies Market Size, Share & Industry Trends Analysis Report By Indication (Cancer, Inflammatory & Autoimmune Disorder and Others), By Country and Growth Forecast, 2023 - 2030


The Europe Bispecific Antibodies Market would witness market growth of 42.1% CAGR during the forecast period (2023-2030).

The most extensively researched use of bispecific antibodies is in cancer immunotherapy particularly in lung, breast, and colon cancer. A bispecific antibody kills the target tumor cell by binding to both the target and cytotoxic cells simultaneously. Technology-advanced solutions for dual targeting methods within the same molecule include bispecific antibodies. The rapid advancement of this therapeutic discipline has been made possible by the effectiveness of BsAbs in cancer as well as noncancer programs.

Rising rates of chronic illnesses like cancer, autoimmune conditions, and infectious diseases, increasing need for targeted medicines, and developments in antibody engineering capabilities are some of the key drivers driving market expansion. People with chronic diseases and mental health disorders also represent a large share of healthcare spending, according to the Centers for Disease Control and Prevention. BsAbs offer a possible path for focused therapies in various disease areas and customized medicine to treat such illnesses.

In Europe, the mental health of numerous individuals has been hampered by the COVID-19 pandemic, which has also highlighted preexisting issues. According to a survey from the UK government, the number of cases of depression in France grew between 2010 and 2020, and people's anxiety increased at the beginning of each lockdown in the nation. All of these figures demonstrate the need for innovative treatments for these problems as well as the need for more R&D investments. Various government support programs and initiatives by major pharmaceuticals have proceeded in this direction, which will be beneficial for the expansion of the regional market.

The Germany market dominated the Europe Bispecific Antibodies Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,194.1 million by 2030. The UK market is experiencing a CAGR of 40.9% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 43.1% during (2023 - 2030).

Based on Indication, the market is segmented into Cancer, Inflammatory & Autoimmune Disorder and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).

Scope of the Study

Market Segments covered in the Report:

By Indication
  • Cancer
  • Inflammatory & Autoimmune Disorder
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Akeso, Inc.
  • Johnson & Johnson (Janssen Global Services, LLC)
  • Taisho Pharmaceuticals Holding Co., Ltd.
  • Immunocore Holdings plc
  • GlaxoSmithKline PLC (GSK)
  • Novartis AG
  • Allergan PLC (AbbVie, Inc.)
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Bispecific Antibodies Market, by Indication
1.4.2 Europe Bispecific Antibodies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Trials and Approvals
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
Chapter 4. Europe Bispecific Antibodies Market by Indication
4.1 Europe Cancer Market by Country
4.2 Europe Inflammatory & Autoimmune Disorder Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Bispecific Antibodies Market by Country
5.1 Germany Bispecific Antibodies Market
5.1.1 Germany Bispecific Antibodies Market by Indication
5.2 UK Bispecific Antibodies Market
5.2.1 UK Bispecific Antibodies Market by Indication
5.3 France Bispecific Antibodies Market
5.3.1 France Bispecific Antibodies Market by Indication
5.4 Russia Bispecific Antibodies Market
5.4.1 Russia Bispecific Antibodies Market by Indication
5.5 Spain Bispecific Antibodies Market
5.5.1 Spain Bispecific Antibodies Market by Indication
5.6 Italy Bispecific Antibodies Market
5.6.1 Italy Bispecific Antibodies Market by Indication
5.7 Rest of Europe Bispecific Antibodies Market
5.7.1 Rest of Europe Bispecific Antibodies Market by Indication
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Trials and Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional & Segmental Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 Akeso, Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 Johnson & Johnson (Janssen Global Services, LLC)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental &Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Acquisition and Mergers:
6.6 Taisho Pharmaceuticals Holding Co., Ltd.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Immunocore Holdings plc
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.7.4 Recent strategies and developments:
6.7.4.1 Partnerships, Collaborations, and Agreements:
6.8 GlaxoSmithKline PLC (GSK)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.9 Novartis AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Allergan PLC (AbbVie, Inc.)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings